Hemophilus influenzae type b (Hib) is a bacterium that can cause a number of serious diseases, especially among young children, like pneumonia and meningitis that account for nearly 20% of deaths globally. The global research and development organization Hilleman Laboratories has conducted the pre-clinical trial for a new Hib vaccine, which can offer affordable treatment to children having viral diseases, revealed a top company official.
The unique formulation derived from the ongoing research will not only bring down the cost of the Hib vaccine, but will also provide a scalable platform for commercial manufacturing.
AdvertisementDavinder Gill, CEO, Hilleman Laboratories, said, "Capsular polysaccharide conjugates of Hib are important components of several mono-or multivalent vaccines for children. However, the access to needy people is limited due to the relative high cost of the Hib vaccine. This new formulation will be a step towards developing a cost-effective and a more immunogenic vaccine. It is an encouraging breakthrough in bridging the gap and making Hib vaccine accessible and affordable."
Gill further added, "A strategic three-step approach was used to identify the efficacy of polysaccharide in preparing a vaccine for Hib. We have already completed the preclinical immunogenicity trial phase which has shown predictive results. Our next step now would be to look at collaboration with like-minded stakeholders who can work together towards cost effective solutions with the aim of bridging existing gaps in a significant way."
The report of this successful trial has been published in Vaccine.
PArtificial Neurons Work Like Real Ones to Treat Neurological Conditions, Paralysis FSSAI Directs Top Ramen Instant Noodles to be Withdrawn from Market M
You May Also Like